Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development and manufacture of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its partners.

Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics, Antitope, PacificGMP and TCRS.

PolyTherics, Antitope, PacificGMP and TCRS have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.

Show more
Cambridgeshire, GB
Size (employees)
139 (est)+53%
Abzena was founded in 2002 and is headquartered in Cambridgeshire, GB
Report incorrect company information

Key People/Management at Abzena

John Burt

John Burt

Julian Smith

Julian Smith


Abzena Office Locations

Abzena has offices in Cambridgeshire, San Diego, Coventry and Bristol
Bristol, US
101e 360 George Patterson Blvd
San Diego, US
e 8810 Rehco Rd
Show all (4)
Report incorrect company information

Abzena Financials and Metrics

Abzena Financials

Abzena's revenue was reported to be £18.65 m in FY, 2017

Revenue (FY, 2017)

18.7 m

Gross profit (FY, 2017)

8.1 m

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

(9.1 m)

EBITDA (FY, 2017)

(7.9 m)

EBIT (FY, 2017)

(9.7 m)

Market capitalization (31-Oct-2017)

38.9 m

Closing share price (31-Oct-2017)


Cash (31-Mar-2017)

4.1 m
Abzena's current market capitalization is £38.9 m.
GBPFY, 2014FY, 2015FY, 2016FY, 2017


5.3 m5.7 m9.9 m18.7 m

Revenue growth, %


Cost of goods sold

1.7 m2.5 m5.3 m10.5 m

Gross profit

3.6 m3.1 m4.5 m8.1 m
GBPFY, 2014FY, 2015FY, 2016FY, 2017


2.8 m15.8 m13.7 m4.1 m

Accounts Receivable

1.8 m1.8 m3.9 m3.7 m


295 k817 k1.4 m1.9 m

Current Assets

5.9 m20.9 m22.1 m11.3 m
GBPFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(3.5 m)(4.7 m)(9.7 m)(9.1 m)

Cash From Operating Activities

(4.1 m)(5 m)(10.7 m)(6.2 m)

Cash From Financing Activities

10.7 m19 m20 m(142 k)

Net Change in Cash

223 k13 m(2.1 m)(9.6 m)
GBPY, 2017


134.2 k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information